ADA Updates 2022 Standards of Care to Reflect New Finerenone, SGLT2 Inhibitor Data

Less than a week before its annual meeting, the American Diabetes Association (ADA) has announced new updates to its Standard of Medical Care in Diabetes, according to an announcement from the ADA.

Published on May 31 in Diabetes Care, the latest updates to the ADA’s Standards of Medical Care in Diabetes—2022 focus on the role of finerenone in patients with type 2 diabetes in chronic kidney disease, the effects of SGLT2 inhibitors on heart failure and renal outcomes in people with type 2 diabetes, and new information on calculating eGFR and inclusion of race for kidney disease diagnoses.

“This is the fifth year that we are able to update the Standards of Care after it has been published through our Living Standards of Care updates, making it possible to give diabetes care providers the most important information and the latest evidence relevant to their practice,” said Robert Gabbay, MD, PhD, chief scientific and medical officer for the ADA, in the aforementioned press release. “With approximately 537 million adults living with diabetes around the world, it’s important to equip providers with the newest research through our guidelines as we learn more.”

Aimed at providing clinicians and patients with the latest evidence-based recommendations for diagnosis and management of type 1, type 2, and gestational diabetes, the Standards of Care represent the latest updates in management from the ADA. Beginning in 2018, the ADA transitioned away from providing annual updates to the online version of the Standards of Care and began to make updates throughout the year with annotations for new evidence for regulatory changes, with this updated version referred to as the Living Standards of Care.

Crafted and approved by the ADA’s Professional Practice Committee, the latest update impact section 10 and section 11 of the document, with the updates detailed within section 10 also receiving approval from the American College of Cardiology. Specific updates to section 10 highlight the inclusion of evidence from the EMPEROR-Preserved, PRESERVED-HF, FIDELIO-DKD, and FIGARO-DKD trials. Specific updates to section 11 included amendments for the inclusion of evidence from EMPEROR-Preserved, FIDELIO-DKD, FIGARO-DKD, and the recommendations on reassessing the inclusion of race in diagnosing CKD from the National Kidney Foundation-American Society of Nephrology Task Force.

This document, “Standards of Medicine Care in Diabetes—2022,” was published in Diabetes Care.